secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001558370-22-013073
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q2 revenue $9.6M (+35% YoY); raises 2022 core revenue growth guidance to ~30%
--------------------------------------------------------------------------------

- Total revenue $9.6M (+35% YoY); core business revenue +45% led by cell therapy +61%.
- Net loss $8.3M (vs $4.4M loss Q2 2021); operating expenses $17.2M (up from $10.7M).
- Cash & investments $240.9M as of June 30, 2022.
- Raised 2022 core revenue growth guidance to ~30%; SPL program-related revenue expected ~$4M.
- Signed 17th SPL agreement in July 2022 with LG Chem.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837022013073/0001558370-22-013073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837022013073/mxct-20220810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-013073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer